Author(s): Xiaoling Lu, Hao L, Min Sun, Kai Li, Lingmin Shen, Tao Wu
Background: L-Arabinose is a non-caloric sugar, which could affect glucose and lipid metabolism andsuppress obesity. However, few reports have described the effect of L-arabinose in metabolic syndrome, acombination of medical disorders that increase the risk of diabetes and cardiovascular disease.Objective: This study was conducted to explore the effects of L-arabinose in rats with metabolic syndromeinduced by a high-carbohydrate, high-fat (HCHF) diet.Methods: After the rat model for metabolic syndrome was successfully established, L-arabinose wasadministrated by oral gavage for 6 weeks. The biochemical index and histological analysis were measured, andthe expression levels of genes related to fatty acid metabolism were analyzed using real-time PCR.Results: Following treatment with L-arabinose, metabolic syndrome rats had an obvious reduction in bodyweight, systolic blood pressure, diastolic blood pressure, fasting blood glucose, triglycerides, total cholesterol,serum insulin, TNF-a, and leptin. Further study showed that treatment with L-arabinose significantlyincreased the expression of mRNA for hepatic CPT-1a and PDK4, but the expression of mRNA for hepaticACCa was reduced.Conclusions: This work suggests that L-arabinose could lower body weight, Lee’s index, and visceral indexand improve dyslipidemia, insulin resistance, inflammation, and viscera function, which indicate that it mightbe a promising candidate for therapies combating metabolic syndrome.